1. TM6SF2 silencing impairs lipid metabolism and trafficking in HepG2 cells carrying the I148M PNPLA3 variant and MBOAT7 deletion. (February 2019) Authors: Longo, M.; Meroni, M.; Rametta, R.; Erconi, V.; Romeo, S.; Fracanzani, A.L.; Valenti, L.; Dongiovanni, P. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models. (February 2020) Authors: Longo, M.; Meroni, M.; Erconi, V.; Alisi, A.; Miele, L.; Rametta, R.; Fracanzani, A.L.; L.Valenti, ; Dongiovanni, P. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models. (March 2021) Authors: Longo, M.; Meroni, M.; Erconi, V.; Carli, F.; Macchi, C.; Ronchi, D.; Sabatini, S.; Paolini, E.; De Caro, E.R.; Alisi, A.; Miele, L.; Soardo, G.; Comi, G.P.; Valenti, L.; Ruscica, M.; Fracanzani, A.L.; Gastaldelli, A.; Dongiovanni, P. Journal: Digestive and liver disease Issue: Volume 53:(2021)Supplement 1 Page Start: S27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗